Moy-Fincher Medical Group
Welcome,         Profile    Billing    Logout  
 8 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozog, David M
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
186
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
NCT05478551: Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

Active, not recruiting
2/3
12
US
Botulinum Toxin, Dysport, BTXa, abobotulinumtoxinA, Normal saline, Placebo
Henry Ford Health System
Scar, Hypertrophic Scar
12/24
12/24
NCT03887377: The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

Enrolling by invitation
2/3
22
US
Botulinum Toxins, Dysport, BTXa, abobotulinumtoxinA, Normal saline, Placebo
Henry Ford Health System, Galderma R&D
Scar, Hypertrophic Scar, Mammary Disorder
12/24
12/24
NCT05766683: Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Active, not recruiting
1
20
US
onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
Henry Ford Health System
Glabellar Frown Lines
06/23
12/24
Fincher, Edgar
No trials found
Moy, Ronald
No trials found
Chipps, Lisa
No trials found

Download Options